The current study showed that the recipient ADAMTS13 rs2285489 C/C genotype, which putatively has lower inducibility of ADAMTS13 than the C/T or T/T genotype [14], was associated with an increased rate of relapse, leading to a lower DFS in patients with hematologic malignancies receiving unrelated BMT than the recipient C/T or T/T genotype. Here, ADAMTS13 is linked to hematologic disorder.